Potential of treating tuberculosis with a polymeric nano-drug delivery system

Swai, Hulda; Semete, Boitumelo; Kalombo, Lonji; Chelule, Paul Kiprono

doi:10.1016/j.jconrel.2008.09.032

Cited by 11 publications

(5 citation statements)

References 1 publication

Supporting

Mentioning

Contrasting

Order By: Relevance

“…NP d H ranges observed in the study are in agreement with previous reports on PLGA NPs . For both empty and rifampicin‐loaded NPs, there was an absence of any particular trend regarding the effect of PEG content on NP hydrodynamic size.…”

Section: Resultssupporting

confidence: 91%

“…NP d H ranges observed in the study are in agreement with previous reports on PLGA NPs. [24,[31][32][33] For both empty and rifampicin-loaded NPs, there was an absence of any particular trend regarding the effect of PEG content on NP hydrodynamic size. There seems to be contradicting evidence in the literature, regarding the effect of PEGylation on PLGA NP size.…”

Section: Np Propertiesmentioning

confidence: 95%

See 1 more Smart Citation

Influence of PEGylation on PLGA nanoparticle properties, hydrophobic drug release and interactions with human serum albumin

Samkange

D’Souza

Obikeze

et al. 2019

Journal of Pharmacy and Pharmacology

View full text Add to dashboard Cite

Objective To evaluate the impact of PEG content on poly(lactic‐co‐glycolic acid) (PLGA) NP physicochemical properties, hydrophobic drug release (rifampicin as a model drug) and human serum protein binding. Methods Rifampicin loaded and unloaded nanoparticles with PEG content of 0–17% (w/w) were prepared by an emulsification–evaporation technique. Nanoparticles were characterized for size, zeta potential and morphology. PEGlyation was confirmed using proton nuclear magnetic resonance (1H NMR). Fluorescence spectroscopy and dynamic light scattering were used to determine nanoparticle‐protein binding, binding constants and stability of nanoparticles in human serum, respectively. Drug loading and release were determined by UV‐VIS spectroscopy and drug release data was mathematically modelled. Key findings A NP PEG content of 17% w/w significantly retarded release of rifampicin from PLGA NPs and altered kinetics of drug release. Stern–Volmer (Ksv) protein binding constants decreased upon PEG incorporation. A 2% w/w PEG was sufficient to significantly reduce protein binding extent to PLGA NPs and maintain particle size distributions. Conclusion The ability to fine tune drug release and formation of protein corona around nanoparticles is crucial to formulation scientists. This study suggests that PLGA NPs with low PEG content might be suitable for extended circulation and rapid drug release and that higher PEG content retards hydrophobic drug release.

show abstract

Section: Resultssupporting

confidence: 91%

Section: Np Propertiesmentioning

confidence: 95%

Influence of PEGylation on PLGA nanoparticle properties, hydrophobic drug release and interactions with human serum albumin

Samkange

D’Souza

Obikeze

et al. 2019

Journal of Pharmacy and Pharmacology

View full text Add to dashboard Cite

show abstract

“…Hulda Swai's (CSIR's Centre for Polymer Technology, South Africa) team have developed nanoparticles (200 nm) of four frontline anti-TB drugs aiming to shorter treatment regimen with single dose drug application that will last for several days or weeks. They showed that the nanoparticles release the drugs into the bloodstream at a slower rate and for a more prolonged period (up to ten days) as compared to conventional therapy [85].…”

Section: Solid Lipid Nanoparticles (Sln)mentioning

confidence: 99%

Present status of nanoparticle research for treatment of Tuberculosis

2011

View full text Add to dashboard Cite

-Nanotechnology has offered enormous improvement in field of therapeutics by means of designing of drug delivery systems and opened the possibility of controlling infections at the molecular level. Nanocarriers can cross biological barriers and are able to target cellular reservoirs of Mycobacterium tuberculosis (M. tuberculosis). Nanoparticle-based systems have significant potential for treatment and prevention of tuberculosis (TB). A variety of nanocarriers have been widely evaluated as potential drug delivery systems for various administration routes. Targeting the drugs to certain physiological sites such as the lymph nodes has emerged as a promising strategy in treating TB with improved drug bioavailability and reduction of the dosing frequency. Nanotechnology based rational targeting may improve therapeutic success by limiting adverse drug effects and requiring less frequent administration regimes, ultimately resulting in more patients compliance and thus attain higher adherence levels. The development of nanoparticle based aerosol vaccine is undergoing which could serve as new platform for immunization. Present article compiles the general physiological aspects of the infection along with new research uptades on nanocarriers used in prevention of tuberculosis. _______________________________________________________________________________________

show abstract

“…In order to mitigate the need for higher total doses and lengthy duration of therapy as well as to improve patient adherence, Swai et al (2008) reformulated RIF, INH, EMB, and PZA into nanoparticulate oral formulations designed for controlled release over prolonged periods. PLGA (poly-lactide glycolide) was utilized in creating a complex nanoemulsion that underwent subsequent spray drying.…”

Section: Lowering Dose Frequencymentioning

confidence: 99%

Nanotechnological innovations in paediatric tuberculosis management: current trends and future prospects

Ajayi,

Poka,

Witika

2024

Front. Drug Deliv.

View full text Add to dashboard Cite

Paediatric Tuberculosis (TB) continues to be a major global cause of morbidity and mortality. Children are more prone to contracting TB, which can spread quickly to extrapulmonary infection sites. Although the pathophysiology of the disease, drug pharmacokinetics, and the therapeutic window in children differ from those of adults, the same drugs used to treat adult TB have long been utilised to treat paediatric TB infections. Since many current formulations such as tablets are unsuitable for children due to difficulty swallowing and risk of choking, adult medications are frequently used by breaking or crushing tablets to obtain a paediatric dose. This can result in inaccurate dosing due to pharmacokinetic differences in children which could subsequently lead to sub-therapeutic or toxic systemic concentrations. In addition, many of the medications used in the treatment of TB and most medicines in general, have a profoundly unpleasant taste to children causing them to reject and spit out medication which contributes to challenges with adherence, ultimately leading to treatment failure. The aforementioned demonstrates a huge need for the development of novel drug delivery formulations that are paediatric-friendly and address the limitations of current dosage forms. This review discusses the currently available oral paediatric formulations, recent developments of novel oral drug delivery systems studied to overcome the current problems associated with the treatment of tuberculosis in paediatrics and provides potential direction for future research through nanotechnology by using a SWOT analysis.

show abstract

Potential of treating tuberculosis with a polymeric nano-drug delivery system

Cited by 11 publications

References 1 publication

Influence of PEGylation on PLGA nanoparticle properties, hydrophobic drug release and interactions with human serum albumin

Influence of PEGylation on PLGA nanoparticle properties, hydrophobic drug release and interactions with human serum albumin

Present status of nanoparticle research for treatment of Tuberculosis

Nanotechnological innovations in paediatric tuberculosis management: current trends and future prospects

Contact Info

Product

Resources

About